Skip to main content
    Z

    Zenas BioPharma, Inc. Common Stock (ZBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $25.40
    +0.54 (+2.17%)

    Market Cap: $1.62B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    33%(3/9)
    Avg Surprise
    -27.13%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.27
    Range$-1.31 - $-1.23
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.31+3.1%
    60d ago$-1.31+3.1%
    30d ago$-1.31+3.1%
    7d ago$-1.31+3.1%
    Current$-1.27
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-2.05
    Range$-2.27 - $-1.83
    2 analysts
    Revenue Consensus
    $-2740000
    Range$-14000000 - $42M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-2.05---
    Sep 26EST
    		-$-1.27---
    Jun 26
    Reported Aug 12
    		$-1.77$-0.89-98.88%Miss-41.6%
    Mar 26
    Reported May 13
    		$-1.46$-1.54+5.19%Beat-82.5%
    Dec 25
    Reported Mar 16
    		$-1.39$-1.19-16.81%Miss-10.3%
    Sep 25
    Reported Nov 12
    		$-1.22$-0.85-43.53%Miss+75.7%
    Jun 25
    Reported Aug 12
    		$-1.25$-1.06-17.92%Miss+55.2%
    Mar 25
    Reported May 15
    		$-0.80$-1.15+30.43%Beat-
    Dec 24
    Reported Mar 25
    		$-1.26$-1.02-23.69%Miss-
    Sep 24
    Reported Nov 12
    		$-5.02$-9.30+46.02%Beat-
    Jun 24
    Reported Aug 22
    		$-2.79$-1.24-125.00%Miss-

    Key Metrics

    Valuation
    P/E Ratio-4.35EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-7766.00%
    ROE-199.00%ROIC-88.52%
    Financial Health
    Debt/Equity1.20xInterest CoverageN/A
    Current Ratio9.93xQuick Ratio9.93x
    Trading Statistics
    Beta-0.88Avg Volume726.01K
    52-Week High$44.6052-Week Low$13.50

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$26.66
    SMA 20$27.85
    SMA 50$30.30
    SMA 200$24.70
    EMA 10$26.43
    EMA 20$27.62
    EMA 50$28.79
    EMA 200$25.96

    MACD

    Line: -1.43Signal: -1.21Hist: -0.22

    ADX

    ADX: 25.6+DI: 10.2-DI: 25.8

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down100.0
    PSAR$29.18

    Bollinger Bands

    Upper Band$32.37
    Lower Band$23.33
    %B Position3245%(Upper)
    Band Width0.23

    RSI (14-Day)

    Neutral
    37.5

    Momentum Oscillators

    Stoch %K11.7
    Stoch %D10.5
    Williams %R-77.1
    ROC (10d)-9.1%
    Momentum-2.54
    CCI (20d)-115.5
    MFI (14d)51.4

    Volatility Measures

    ATR (14d)$1.89(7.4%)
    StdDev (20d)2.26
    Hist Vol65.0%(High)

    Volume Flow

    VWAP$25.20
    OBV13.2M
    AD Line20.1M
    CMF (20d)-0.291

    Volume Metrics

    Avg Vol (20d)734.9K
    Vol Ratio0.6x
    VWMA (20d)$28.32

    Pivot Points

    R3$28.20
    R2$27.35
    R1$26.10
    Pivot Point$25.25
    S1$24.00
    S2$23.15
    S3$21.90

    Advanced Oscillators

    TSI-23.74
    Ultimate Osc38.5
    KST-149.73

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.00M$0$10.00M$0$0$10.00M$5.00M$0$0$0$0$50.00M
    Cost of Revenue$0$0$10,000$0$0$0$33,000$0$0$0$20.42M$0
    Gross Profit$1.00M$0$-10,000$0$0$10.00M$5.00M$0$0$0$-20,418,000$50.00M
    Operating Expenses$108.66M$77.35M$237.98M$52.58M$55.16M$47.33M$60.62M$40.98M$39.70M$27.58M$4.36M$14.38M
    R&D$92.91M$60.44M$222.39M$39.40M$43.03M$34.91M$49.16M$33.53M$33.81M$22.64M$20.42M$9.35M
    SG&A$15.75M$16.91M$15.59M$13.18M$12.14M$12.41M$11.47M$7.45M$5.89M$4.93M$4.16M$5.02M
    Operating Income$-107,659,000$-77,350,000$-237,984,000$-52,580,000$-55,163,000$-37,330,000$-55,624,000$-40,984,000$-39,702,000$-27,578,000$-24,779,000$35.62M
    Interest Income$6.60M$3.02M$0$0$2.74M$3.39M$0$0$0$0$0$0
    Interest Expense$10.30M$6.63M$2.35M$0$0$0$0$0$0$222,000$0$16,000
    Income Before Tax$-111,342,000$-80,987,000$-240,336,000$-51,499,000$-52,203,000$-33,778,000$-52,176,000$-38,606,000$-37,977,000$-27,800,000$-24,286,000$35.61M
    Income Tax Expense$114,000$0$106,000$0$20,000$-205,000$429,000$0$0$0$301,000$0
    Net Income$-111,456,000$-80,987,000$-240,442,000$-51,499,000$-52,223,000$-33,573,000$-52,605,000$-38,606,000$-37,977,000$-27,800,000$-24,587,000$35.61M
    EBITDA$-108,926,000$-77,478,000$-245,571,000$-51,681,000$-55,869,000$-37,531,000$-60,870,000$-38,570,000$-37,790,000$-27,767,000$-24,256,000$35.61M
    EBIT$-107,643,000$-77,374,000$-245,160,000$-51,499,000$-54,946,000$-37,172,000$-60,301,000$-38,606,000$-37,825,000$-27,800,000$-24,286,000$35.61M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ZBIO

    News

    H.C. Wainwright reiterates Zenas Biopharma stock rating at buy By Investing.com

    H.C. Wainwright has reiterated a Buy rating and a $44.00 price target for Zenas Biopharma (NASDAQ:ZBIO) after reviewing new data on its obexelimab drug candidate. The data from the Phase 3 INDIGO open-label extension...

    Investing.com Nigeria•10/13/26•Bullish

    HC Wainwright & Co. reiterates Buy rating on Zenas BioPharma, $44 price target

    HC Wainwright & Co. has reiterated its Buy rating on Zenas BioPharma (ZBIO) with a price target of $44.00, representing a potential upside of 66.7% from its previous closing price. The positive outlook is supported by...

    TradingView•10/13/26•Bullish

    Zenas Bio Presents Positive Phase 3 Obexelimab Data Showing 93% 12‑Month Flare‑Free Rate

    Zenas Bio (ZBIO) announced positive Phase 3 INDIGO data for obexelimab, demonstrating sustained clinical activity and reduced steroid toxicity...

    TradingView•10/13/26•Bullish

    Zenas BioPharma (ZBIO) Is Down 5.1% After New Phase 3 Obexelimab IgG4-RD Data Release

    Zenas BioPharma (ZBIO) shares are down 5.1% following the release of new Phase 3 INDIGO data for obexelimab in immunoglobulin G4-related disease (IgG4-RD). The data highlighted long-term flare protection...

    Yahoo Finance•10/13/26•Neutral

    Zenas BioPharma (ZBIO) FDA Approvals, PDUFA Dates & Drug Alerts 2026

    This article details Zenas BioPharma's (ZBIO) FDA regulatory milestones for its drug pipeline, including Obexelimab, Orelabrutinib...

    MarketBeat•10/13/26•Bullish

    ZBIO Valuation and Fair Value

    P/E
    -4.3x
    P/B
    6.5x
    See GNG's fair value

    ZBIO Profitability: Margins, ROIC and FCF

    Operating margin
    -7766.0%
    Net margin
    0.0%
    ROIC
    -88.5%
    ROE
    -199.0%
    FCF margin
    -26097.4%

    ZBIO Competitors

    CompanyTicker
    Forte Biosciences IncFBRX
    Kestra Medical Technologies, Ltd. Common StockKMTS
    Omnicell IncOMCL
    Ocular Therapeutix IncOCUL
    Nuvation Bio IncNUVB
    Compass Pathways PlcCMPS
    Biohaven Ltd.BHVN
    RAPT Therapeutics IncRAPT

    Sector: Healthcare

    ZBIO Analyst Ratings

    Consensus
    Buy
    Analysts
    8
    Strong Buy
    0
    Buy
    7
    Hold
    1
    Sell
    0
    Strong Sell
    0

    ZBIO Bull Case vs Bear Case

    Bull case

    • 87.5% of ZBIO's analyst ratings are Buy or Strong Buy.

    Bear case

    • ZBIO beat EPS estimates in 37.5% of its last 8 reported quarters.
    • ZBIO's quarterly revenue changed -100.0% year over year.

    ZBIO Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -14.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.27
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 1 down

    Frequently Asked Questions About ZBIO

    Does ZBIO pay dividends?

    Zenas BioPharma, Inc. Common Stock (ZBIO) does not currently pay a regular dividend.

    What is ZBIO's market cap?

    Zenas BioPharma, Inc. Common Stock (ZBIO) has a market capitalization of $1.62B with a current stock price of $25.40.

    Related stocks

    Sector: Healthcare

    All stocks starting with Z

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In